Gynecologic DiseaseNCT07279571
GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education
An observational study of Gynecologic Disease, run by University of Southern California at 1 site in United States.
Trial summary
This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Gynecologic Disease
- What is being tested?
- Non-Interventional Study
- How many people
- 48 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Jun 2026to 9 Jun 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Patients of the LA General gynecologic oncology clinic who meet the eligibility criteria.
Who may be able to join
- Patient of the LA General gynecologic oncology clinic
- Age 18 years or older
- Previously obtained the HPV vaccination (initial chatbot evaluation)
- Eligible for HPV vaccination (pilot intervention; age <46)
- Willing and able to provide informed consent
- Patient of the LA General gynecologic oncology clinic
- Age 18 years or older
- Obtained the HPV vaccine
Who cannot join
- Patients who do not speak English or Spanish
- Patients who do not provide informed consent
- HPV vaccination rate (Aim 2):
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Los Angeles General Medical Center
Los Angeles, California, 90033
Kimberly M. Arieli, 323-865-3000, Kimberly.Arieli@med.usc.edu
Xiaoyue M. Guo
About this study
This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource.
Read the detailed description
AIM 1: Evaluate use of an AI chatbot for HPV vaccine counseling:
PRIMARY OBJECTIVE:
- To determine patient satisfaction with using an AI chatbot for HPV vaccine counseling.
SECONDARY OBJECTIVE:
- To understand how patients currently obtain information about cancer care, vaccines, and artificial intelligence.
II. To describe patient experience with the AI-chatbot for vaccine counseling.
AIM 2: Increase rates of HPV vaccine uptake:
PRIMARY OBJECTIVE:
- To evaluate if implementation of an AI chatbot for HPV vaccine counseling can affect the HPV vaccination rate of new patients served in the gynecologic oncology clinic.
OUTLINE: This is an observational study.
Patients complete a survey on study.
- Conditions
- Gynecologic Disease
- Being tested
- Non-Interventional Study
- Medical subject headings
- Genital Diseases, Female
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-Interventional StudyOther
Also called Non-Interventional Observational Study, Noninterventional (Observational) Study
Non-interventional study
| Study group | Role | What they receive |
|---|---|---|
| Observational | Patients complete a survey on study. Receives: Other: Non-Interventional Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Satisfaction Scores
Patients will complete a survey to assess their satisfaction with using an AI chatbot for HPV vaccine counseling.
Measured: Up to 1 year
HPV Vaccination Rate
HPV vaccination rate for patients who received the HPV vaccine counseling with the AI-chatbot
Measured: Up to 1 year
Secondary outcomes (1)
Demographics of patients
Will be analyzed using a qualitative description of the demographics of patients involved in this specific study.
Measured: Up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2025
- Study start12 Jun 2026
- Primary completion9 Jun 2027 (estimated)
- Study completion9 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gynecologic DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Xiaoyue M Guo, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07279571
- Sponsor's protocol ID
- 5U-25-1
- Other IDs
- NCI-2025-03594, UP-25-00331, 5U-25-1, P30CA014089
- Status last verified
- Aug 2026
- First submitted
- 20 Nov 2025
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education
- ClinicalTrials.gov ID
- NCT07279571
- Acronym / sponsor ID
- 5U-25-1
- Conditions
- Gynecologic Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 12 Jun 2026 (actual)
- Primary completion
- 9 Jun 2027 (estimated)
- Study completion
- 9 Jun 2028 (estimated)
- First posted
- 12 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource.
Detailed description
AIM 1: Evaluate use of an AI chatbot for HPV vaccine counseling:
PRIMARY OBJECTIVE:
- To determine patient satisfaction with using an AI chatbot for HPV vaccine counseling.
SECONDARY OBJECTIVE:
- To understand how patients currently obtain information about cancer care, vaccines, and artificial intelligence.
II. To describe patient experience with the AI-chatbot for vaccine counseling.
AIM 2: Increase rates of HPV vaccine uptake:
PRIMARY OBJECTIVE:
- To evaluate if implementation of an AI chatbot for HPV vaccine counseling can affect the HPV vaccination rate of new patients served in the gynecologic oncology clinic.
OUTLINE: This is an observational study.
Patients complete a survey on study.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational | – | Other: Non-Interventional StudyPatients complete a survey on study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients of the LA General gynecologic oncology clinic who meet the eligibility criteria.
Key inclusion criteria (8 listed)
- Patient of the LA General gynecologic oncology clinic
- Age 18 years or older
- Previously obtained the HPV vaccination (initial chatbot evaluation)
- Eligible for HPV vaccination (pilot intervention; age <46)
- Willing and able to provide informed consent
Key exclusion criteria (4 listed)
- Patients who do not speak English or Spanish
- Patients who do not provide informed consent
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-Interventional StudyAlso: Non-Interventional Observational Study, Noninterventional (Observational) StudyNon-interventional study | Other | Observational |
Primary outcome
Patient Satisfaction Scores
Time frame: Up to 1 year
Patients will complete a survey to assess their satisfaction with using an AI chatbot for HPV vaccine counseling.
HPV Vaccination Rate
Time frame: Up to 1 year
HPV vaccination rate for patients who received the HPV vaccine counseling with the AI-chatbot
1 secondary outcome
Demographics of patients
Time frame: Up to 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
Related trials for Gynecologic Disease
RecruitingPhase 3
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
Gynecologic Cancer, Anemia
RecruitingObservational study
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Cancer, Cancer Diagnosis
Recruiting
Methylation Analyses for Gynaecological Research Through Home-based Self-sampling
Healthy Adult Participants, Gynecological Disease
Active, not recruitingObservational study
Diet, Hepcidin, and Chemotherapy RDI
Breast Cancer Female, Ovarian Cancer
Not yet recruiting
Remote Robotic Surgery for Gynecologic Cancer: A Safety and Effectiveness Study
Endometrial Cancer, Cervical Cancer (Early Detection)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xiaoyue M Guo principal investigator
University of Southern California
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gynecologic Disease, run by University of Southern California at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Satisfaction Scores (time frame: Up to 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.